Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 09:45 AM ET – S&P Global Services PMI (Mar)

✓ 10:00 AM ET – ISM Non-Manufacturing PMI (Mar)

✓ 10:00 AM ET – ISM Non-Manufacturing Prices (Mar)

✓ 10:30 PM ET – Crude Oil Inventories

PREMARKET SNAPSHOT 📈

US stock futures dip on Wednesday, with the Dow Jones leading the decline by over 1%.

SECTOR SNAPSHOT ✨

US markets see red across most sectors, with Health Care taking the biggest hit, down 1.62%.

Unusual Volume

📈 Trio Petroleum Corp. (TPET) jumped 43.76% to $0.15 on a whopping 206.35 million shares traded.

📈 Investors went wild, sending C3is Inc (CISS) stock soaring 13.30% to $0.04 on a massive volume of 140.07 million shares.

📈 Abnormal activity shook VivoPower International PLC (VVPR), pushing it up 306.90% to $5.90 on a whopping 120.97 million shares traded. This increase followed news that the company has entered into a binding heads of agreement whereby it will exclusively negotiate to consummate a business combination agreement to merge with Cactus Acquisition Corp. 1 Limited.

📈 KULR Technology Group Inc (KULR) stock recently closed 71.71% upper at $0.70 on substantial volume of 106.17 million shares. This unusual activity came after the company unveiled a commitment exceeding $1 million with H55 Inc., a pioneer and global leader in electric propulsion.

📈 Gamida Cell Ltd (GMDA) increase by 17.96% in a single trading session, with abnormally high trading volume of 97.15 million shares.

Premarket Movers

OneMedNet Corporation (ONMD) experiences a substantial 22.23% surge in pre-market trading after announcing that it has entered into a definitive securities purchase agreement with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes.

AVanda Pharmaceuticals Inc. (VNDA) sees a significant 28.13% increase, reaching a pre-market price of $5.01 after the company announced that the FDA has approved Fanapt® (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

LAMF Global Ventures Corp. I (LGVC) demonstrates a noteworthy 94.99% surge, with a pre-market price of $21.00. The company’s shareholders approved previously announced business combination with Nuvo Group Ltd.

Important FDA 

Recently Announced

Vanda Pharmaceuticals (VNDA) marked a significant achievement with the FDA's recent approval of Fanapt for expanded use in treating bipolar I disorder in adults. The FDA decision on April 2, 2024, greenlit Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, signaling a positive development for the company's drug portfolio.

Regeneron Pharmaceuticals (REGN) faced regulatory hurdles with the FDA's issuance of Complete Response Letters (CRLs) for Odronextamab on March 25, 2024. The CRLs were specific to the drug's Biologics License Application (BLA) for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, posing challenges for the company's therapeutic pipeline.

Esperion Therapeutics (ESPR) celebrated a significant regulatory win with the FDA's approval of expanded labels for NEXLETOL and NEXLIZET. The FDA decision on March 31, 2024, granted broadened labels for these drugs, allowing for the prevention of heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use. 

Upcoming Announcements

Supernus Pharmaceuticals, Inc. (SUPN) anticipates the FDA's verdict on SPN-830 come April 5, 2024. SPN-830 is under review for its potential as a continuous treatment for motor fluctuations (OFF episodes) in Parkinson's disease. The FDA's decision is currently pending.

Johnson & Johnson (JNJ) also awaits the FDA's decision on April 5, 2024. Carvykti (sBLA), their drug, is being assessed for expanded usage in treating adult patients with relapsed or refractory multiple myeloma, who have undergone at least one prior line of therapy. The final decision from the FDA is yet to be determined.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.